Theravance Biopharma Inc. (NASDAQ: TBPH) is -5.88% lower on its value in year-to-date trading and has touched a low of $7.53 and a high of $11.83 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The TBPH stock was last observed hovering at around $10.61 in the last trading session, with the day’s loss setting it -0.05% off its average median price target of $12.00 for the next 12 months. It is also 44.42% off the consensus price target high of $19.00 offered by 6 analysts, but current levels are -17.33% lower than the price target low of $9.00 for the same period.
Currently trading at $10.56, the stock is 3.05% and -0.30% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.68 million and changing -0.47% at the moment leaves the stock 6.01% off its SMA200. TBPH registered 14.66% gain for a year compared to 6-month gain of 15.54%.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
The stock witnessed a 1.73% loss in the last 1 month and extending the period to 3 months gives it a -2.13%, and is 4.14% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.34% over the week and 4.09% over the month.
Theravance Biopharma Inc. (TBPH) has around 111 employees, a market worth around $665.81M and $51.30M in sales. Distance from 52-week low is 40.24% and -10.73% from its 52-week high. The company has generated returns on investments over the last 12 months (-21.50%).
Theravance Biopharma Inc. (TBPH) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Theravance Biopharma Inc. (TBPH) is a “Hold”. 6 analysts offering their recommendations for the stock have an average rating of 2.70, where 1 rate it as a Hold and 0 think it is a “Overweight”. 3 of the analysts rate the stock as a “Buy”. 1 analysts have rated the stock as a Sell or Underperform.
Theravance Biopharma Inc. is expected to release its quarterly report on 05/09/2023.The EPS is expected to grow by 66.90% this year
Theravance Biopharma Inc. (TBPH) Top Institutional Holders
The shares outstanding are 67.33M, and float is at 59.94M with Short Float at 13.53%.
Theravance Biopharma Inc. (TBPH) Insider Activity
A total of 16 insider transactions have happened at Theravance Biopharma Inc. (TBPH) in the last six months, with sales accounting for 16 and purchases happening 0 times. The most recent transaction is an insider sale by Farnum Rhonda, the company’s SVP, COMM & MEDICAL AFFAIRS. SEC filings show that Farnum Rhonda sold 4,000 shares of the company’s common stock on Mar 09 at a price of $10.20 per share for a total of $40800.0. Following the sale, the insider now owns 0.36 million shares.
Theravance Biopharma Inc. disclosed in a document filed with the SEC on Mar 06 that GRAHAM RICHARD A (SVP, RESEARCH & DEVELOPMENT) sold a total of 2,323 shares of the company’s common stock. The trade occurred on Mar 06 and was made at $10.05 per share for $23346.0. Following the transaction, the insider now directly holds 0.37 million shares of the TBPH stock.
Still, SEC filings show that on Dec 14, Winningham Rick E (CHIEF EXECUTIVE OFFICER) disposed off 50,000 shares at an average price of $11.19 for $0.56 million. The insider now directly holds 1,350,797 shares of Theravance Biopharma Inc. (TBPH).
Theravance Biopharma Inc. (TBPH): Who are the competitors?
The company’s main competitors (and peers) include Collegium Pharmaceutical Inc. (COLL) that is trading 34.68% up over the past 12 months and Cumberland Pharmaceuticals Inc. (CPIX) that is -19.07% lower over the same period. Corcept Therapeutics Incorporated (CORT) is -8.39% down on the 1-year trading charts.
